Background: There are more than 90 serotypes of Streptococcus pneumoniae, with varying biologic and epidemiologic properties. Animal studies suggest that carriage induces an acquired immune response that reduces duration of colonization in a nonserotypespecific fashion. Methods: We studied pneumococcal nasopharyngeal carriage longitudinally in Kenyan children 3-59 months of age, following up positive swabs at days 2, 4, 8, 16, and 32 and then monthly thereafter until 2 swabs were negative for the original serotype. As previously reported, 1868/2840 (66%) of children swabbed at baseline were positive. We estimated acquisition, clearance, and competition parameters for 27 serotypes using a Markov transition model. Results: Point estimates of type-specific acquisition rates ranged from 0.00025/d (type 1) to 0.0031/d (type 19F). Point estimates of time to clearance (inverse of type-specific immune clearance rate) ranged from 28 days (type 20) to 124 days (type 6A). For the
serotype most resistant to competition (type 19F), acquisition of other serotypes was 52% less likely (95% confidence interval ϭ 37%-63%) than in an uncolonized host. Fitness components (carriage duration, acquisition rate, lack of susceptibility to competition) were positively correlated with each other and with baseline prevalence, and were associated with biologic properties previously shown to associate with serotype. Duration of carriage declined with age for most serotypes. Conclusions: Common S. pneumoniae serotypes appear superior in many dimensions of fitness. Differences in rate of immune clearance are attenuated as children age and become capable of more rapid clearance of the longest-lived serotypes. These findings provide information for comparison after introduction of pneumococcal conjugate vaccine. 
S
treptococcus pneumoniae is a bacterium that commonly colonizes the nasopharynx of children, causing a range of diseases when it invades normally sterile sites. Pneumococcal disease causes an estimated 11% of deaths in children Ͻ5 years of age worldwide 1 and considerable morbidity and mortality in adults. [2] [3] [4] [5] The nasopharynx is the site from which pneumococci are ordinarily transmitted, 6 and nasopharyngeal carriage is thought to precede disease. 6 More than 90 pneumococcal serotypes-defined by the polysaccharide capsule-are known. 7 Capsular variation has important consequences for many aspects of the host-pathogen interaction. 8 -15 Several immune mechanisms protect against nasopharyngeal carriage, thereby reducing disease risk and disrupting transmission. Licensed pneumococcal conjugate vaccines confer serotype-specific, antibody-mediated immunity, which reduces nasopharyngeal carriage, 16 invasive disease, 17 and mortality. 18 For some serotypes, there is evidence that naturally acquired anticapsular antibody can also protect against carriage. 19 -21 There is also acquired immunity to colonization that is not serotype-specific. 22 A likely mechanism of this immunity 23 is an antigen-specific CD4 ϩ T cell response, which acts via interleukin-17A secretion and neutrophil recruitment to hasten clearance of colonization in older (more immune) hosts. 24, 25 Some next-generation pneumococcal vaccines are designed to elicit this form of immunity. Longitudinal studies are required to assess how the development of immunity to pneumococci in children determines the age-and serotype-specific pattern of carriage and disease. [27] [28] [29] [30] [31] [32] Knowledge of this process is necessary to improve our understanding of pneumococcal diversity in unvaccinated populations 33 and the impact of vaccines on this diversity and resulting patterns of disease. 13, 34, 35 Determinants of serotype frequency include rates of acquisition of carriage and clearance of carriage, as well as the strength of competitive interactions that determine whether a subsequent serotype can colonize a person already colonized with one serotype. 27, 30, 36, 37 A large longitudinal study of pneumococcal carriage undertaken in children 3-59 months old in Kilifi, Kenya 38, 39 offers an opportunity to estimate these parameters. Previously, we estimated acquisition and loss rates from this study, using a separate model for each serotype and assuming constant hazards of acquisition and loss. 38 Here, we extend this work using a single, more detailed model that includes states for colonization with each of the 27 most common serotypes (collectively accounting for 95% of all baseline colonization, plus a category for "other" serotypes) and simultaneously estimates acquisition and clearance rates of each serotype, as well as a parameter measuring each serotype's competitive ability. We also examine age-related changes in serotype-specific parameters. Questions motivating this analysis were as follows: (1) How do serotypes differ in acquisition rates, immune clearance rates, and susceptibility to competitive encroachment by other types? (2) If such differences are found, are they consistent with in vitro measures of capsular structure and function that have previously been found to predict serotype carriage prevalence? 15 (3) For each serotype, does time to clearance of pneumococcal carriage decrease with age, consistent with animal experimental studies of immune maturation 40 and acquired immunity following exposure to carriage? 25 
METHODS

Study Population
The study was conducted among residents of the Kilifi Health and Demographic Surveillance Study area, Kilifi, Kenya. This study is a longitudinal recording of residents in a well-defined geographic area (population about 250,000) around Kilifi District Hospital on the Kenyan coast, updated through continuous census for vital events every 4 months. The study was approved by the Kenya Medical Research Institute/National Ethical Review Committee and The Oxford Tropical Research Ethics Committee, and written informed consent was obtained for all participants.
Study Design
The study has been described elsewhere. 38, 39 Briefly, we randomly selected 3570 children 3-59 months of age from the surveillance study register and approached their parents/ guardians for consent between October 2006 and November 2008. Exclusion criteria included migration or planned migration from the study area, lack of parent/guardian consent, or illness that prevented the taking of a nasopharyngeal swab. Children whose day-1 ("baseline") swab cultures were positive for pneumococcus were resampled on approximately days 2, 4, 8, 16, and 32 and monthly thereafter, until obtaining 2 consecutive swabs, each of which had either no pneumococcal growth or a pneumococcal serotype different from the baseline serotype. Once 50 complete durations had been documented for a serotype, additional children found with that serotype at baseline were not followed up, but baseline prevalence estimates included individuals beyond the 50-person limit. As previously reported, 38, 39 the study contained baseline swabs on 2840 children, of whom 1868 (66%) carried pneumococci at baseline.
Data Analysis
We defined a Markov transition model with 29 states, corresponding to uncolonized with S. pneumoniae (state 0), colonized with each of the 27 serotypes most commonly recovered in baseline samples (states 1-27), or colonized with any other serotype (state 28). For each "serotype" (including other) i in the model, the transitions within this Markov model are as follows: acquisition (transition from uncolonized state 0 to state i, occurring with hazard rate a i ), clearance (transition from state i to state 0, occurring with hazard rate b i ), and change of serotype (transition from state i, which we call "resident," to state j, which we call "challenge," occurring with hazard rate c ij ). All hazards were assumed to be time-homogeneous and, in the basic model, identical for all hosts. Figure 1 shows a simplified version of Markov Transition Model this model (with 2 individual serotypes, labeled 1 and 2, and an "other serotype" category). Table 1 summarizes these model parameters.
In this study, the processes of clearance and change of serotype were observed (although interval-censored). We assumed that, for a child who completed follow-up (2 consecutive visits with other than the baseline serotype), (1) the first of these 2 visits indicated the state to which they switched after the baseline state, (2) the change occurred sometime between the last visit positive for baseline type and the first of the 2 consecutive visits not positive for it, and (3) no other changes occurred unobserved during the period of follow-up. We also assumed that, at most, one event occurred in an interval between observations. Thus, the child's likelihood contribution was similar to that of an interval-censored observation in a competing risks setting (where the competing risks are clearance or switching to each of the other types), while children who are censored before 2 consecutive visits negative for the baseline serotype are assumed to have been censored at the time of the last visit.
Acquisition from the uncolonized state was never observed because subjects uncolonized at baseline are censored after their first visit. Instead, we estimated acquisition rates by assuming that the baseline sample represents a sample from the stationary distribution of the Markov process, which is a deterministic (but algebraically complicated) function of the hazards.
For prevalence estimation in the baseline sample, we included all 2840 children, indexed by x. For estimating rates of clearance and switches to other serotypes, we included only those children who were colonized at baseline (denoted o x ϭ 0) and from whom at least 3 swabs were taken in total (such that 2 swabs negative for the baseline type might be observed, denoted y x ϭ 1).
Thus, we can compute a likelihood for the data on each individual x with baseline state i x , ending state j x , time of sampling t x for the last swab positive for type i before the 2 negatives, time of sampling u x for the first of 2 consecutive swabs negative for type i x or (if this does not occur), the last swab positive for type i x ; indicator q x ϭ 1 if individual x was still carrying i x at time u x and q x ϭ 0 otherwise, and indicator m x ϭ 1 if individual x had cleared carriage at time u x , and m x ϭ 0 otherwise. Suppressing the subscript x for readability, each child makes an independent likelihood contribution p 0 if uncolonized at baseline and p i if carrying type i at baseline, where p i is the stationary probability (a function of the a i , b i , c ij ) of being in state i (including uncolonized, i ϭ 0).
In addition, for children positive at baseline who receive at least 3 swabs, those in whom no transition has occurred by time u contribute likelihood e
, where Overall the likelihood contribution for individual x is Table 2 .) The likelihood of the full data is the product of this likelihood over all subjects.
For n serotypes, such a model would have n 2 ϩ n independent rates, more than are feasible to fit even with this large data set. To reduce dimensionality, we considered 4 models, each of which independently estimates the 2n acquisition and clearance rates but constrains the "change of serotype" rates c ij in various ways.
A. "Fixed susceptibility to competition" in which the acquisition rate of type j among children colonized with type i is a fixed constant r (susceptibility to competition) times the acquisition rate among uncolonized persons: c ij ϭ ra j . B. "Type-specific susceptibility to competition" in which the acquisition rate of type j among children colonized with type i is a resident-type-specific susceptibility to competition r i times the acquisition rate among uncolonized persons: c ij ϭ a j r i . C. "Type-specific challenge strength" in which the acquisition rate of type j among children colonized with type i is specific to type j, but independent of the serotype i that is resident and not necessarily proportional to the acquisition rate of j among uncolonized children: c ij ϭ s j . D. "Full model" (combining B and C) in which the acquisition rate of type j among children colonized with type i is a resident-type-specific constant r i times a challengetype-specific constant s j :c ij ϭ r j s j .
These models are summarized in Table 3 . We fit each model by maximum likelihood using the optim routine, Broyden-Fletcher-Goldfarb-Shanno (BFGS) and limited-memory BFGS with box constraints (L-BFGS-B) methods, in R 2.11.1, 41 ranked them by Akaike information criterion (AIC), and assessed each for face validity and stability of estimates.
Correlations of Serotype Characteristics Measured in This Study and in Previous Studies
Pearson correlations among various properties of serotypes from this study were estimated. In these correlations, prevalence was logit-transformed; acquisition and loss rates and susceptibility to competition were logtransformed. 42 We assessed the relationship of specific laboratorymeasured characteristics of serotypes (number of carbons per polysaccharide repeat unit, a measure of capsule complexity and predictor of capsule thickness; and survival of the serotype in a standardized genetic background when exposed to human neutrophils in a surface killing assay 15 ) to the estimated rates from model B by Spearman rank correlation coefficients.
Confidence intervals for Pearson correlations were calculated using the delta method. 43 We transformed the model parameters into the arctanh of the relevant correlations and 
Individual colonized at baseline with type i receives at least 3 swabs and is observed to clear carriage in the interval (t, u)
where the bracketed term is the likelihood that some event (where the total hazard is h i ) occurs in the interval (t, u), and the fraction is the probability that of all possible events, clearance is the first event that occurs Individual colonized at baseline with type i receives at least 3 swabs and is observed to switch to type j in the interval (t, u)
where the bracketed term is the likelihood that some event (where the total hazard is h i ) occurs in the interval (t, u), and the fraction is the probability that of all possible events, switch to type j is the first event that occurs 
Markov Transition Model used the gradient of this transformation to perturb the asymptotic distribution of the parameters' maximum likelihood estimates. We used the arctanh transformation, following Fisher's variance stabilizing z-transformation, 44 to calculate the confidence intervals on a scale where the normal approximation would be appropriate. Confidence intervals in the arctanh scale were then mapped back to the standard correlation scale.
P values for Spearman correlations were calculated using the asymptotic t test statistic for the permutation test. 45 
Effect of Age on Serotype-specific Measures
We repeated parameter estimates within approximate terciles of age, with age cutoffs at 22 and 41 months. Because of data sparsity, we considered the 23 most common serotypes at baseline (rather than the 27 serotypes we used in the all-ages analysis) and combined the remaining ones in another category. Because data for some serotypes in some age groups were sparse, we used the asymptotically normal sampling distribution of the all-ages estimates to construct weak priors for each of the age-specific analyses.
Detailed Analyses of Longitudinal Samples
We compared the frequency of each serotype in baseline samples with that in follow-up samples that were different from baseline. We also assessed whether particular serotypes appeared together at adjacent time points in a given child more often than expected from their population frequencies (eg, whether particular serotypes tended to colonize particular hosts or to be better at "sharing" a host). We did so first by identifying every "transition pair" of adjacent samples from a single host in which pneumococci of different serotypes were present in the 2 samples, and noting the starting and ending serotype in each pair, creating a histogram of the number of pairs that (for example) started with type 19F and ended with 23F. We then created 400 permutations of these pairs (permuting the ending serotype) and obtained an expected value and distribution of the number of pairs with each start and end serotype. After correcting for the appearance of pairs with the same start and end serotype in the permutations, we calculated the observed-minus-expected number of pairs for each pair of serotypes and created a smoothed curve of the 95th percentile of the observed-expected statistic as a function of the number of expected pairs. Serotype pairs falling outside this 95th percentile were examined.
RESULTS
Details of the frequencies and types of observations used in the model are shown in eTable 1 (http://links.lww.com/EDE/A581).
Model Selection
Maximum likelihood estimates converged for all 4 models ( Table 1 ). The best-fitting models by AIC were models B (with type-specific susceptibility to competition) and D (the full model). However, model B provided stable estimates and finite confidence intervals for all parameters for all 28 serotypes, whereas the estimates in model D were extremely unstable, including confidence intervals spanning zero to infinity, even for quantities associated with some common serotypes, such as 19F and 23B. For this reason, we proceeded to analyze only model B. Figure 2A shows the estimated time to clearance by serotype (reciprocal of clearance rate), showing serotypes in declining order of baseline prevalence. Point estimates of time to clearance ranged from 28 days for type 20 to 123 days for type 6A. Figure 2B shows the estimated rates of acquisition by serotype, preserving the same order of serotypes. Point estimates of acquisition rates ranged from 0.00025/d for type 1 to 0.0031/d for type 19F. Figure 2C shows serotype-specific susceptibility to competition, defined as the rate at which individuals carrying that serotype switch to carry another serotype, relative to the rate at which that other serotype colonizes an uncolonized person r i ϭ c ij /a j . Point estimates ranged from 0.48 (serotype 19F) to 2.1(serotype 33B). Although confidence intervals for r i for many serotypes are strictly Ͻ1.0 (giving evidence for competition), the serotypes with point estimates Ͼ1.0 are mainly the rarest ones, most of which have confidence intervals that dip Ͻ1.0. Thus, these results are consistent with the presence of competition by all strains, although its strength is uncertain for the rarer types. Table 4 shows the correlation coefficients among prevalence, acquisition rate, clearance rate, and susceptibility to competition. The first 4 properties are correlated with each other in such a way that the most "fit" serotypes on each property tend to do best on the others too: serotypes with higher prevalence tend to have lower hazards of clearance, are less susceptible to competition, and have higher rates of acquisition.
Time to Clearance
Acquisition Rate Among Uncolonized Persons
Susceptibility to Competition
Correlations Among Fitness Components and With Laboratory Measurements
We also tested the hypothesis that these epidemiologic properties of serotypes would correlate with 2 additional properties of serotypes that we have previously studied: the biochemical complexity of the capsular polysaccharide repeat unit (measured as number of carbons per repeat unit) and in vitro resistance to nonopsonic surface phagocytosis by human neutrophils. 15 For the subset of serotypes for which these measures are available, such correlations are suggested with each of the studied epidemiologic properties. Greater resistance to surface phagocytosis is associated with higher acquisition rate, lower clearance rate, and better competitive ability; to a lesser degree, simpler capsular polysaccharide repeat units are also associated with these properties. 
Changes in Rates and Susceptibility to Competition With Age
Time to clearance became faster with age for virtually every serotype (Fig. 3A) . The serotype-specific time to immune clearance fell from a median (interquartile range ͓IQR͔) of 105 days (79 -137) in those under 22 months to 39 days (30 -43) in those 41 months or older. The estimated time to clearance of a serotype among children Ͻ22 months was nearly uncorrelated with that in the 2 older age groups, suggesting that the factors predicting duration of colonization in the younger age groups become less important in older children. The serotypes with the longest time to clearance in young children had the greatest proportional decline in time to clearance (eFig. 1, http://links.lww.com/EDE/A581) (log values, Pearson r ϭ Ϫ0.86, ͓95% CI ϭ Ϫ0.71 to Ϫ0.94͔).
Acquisition rates showed no obvious trend with age (Fig. 3B ). For several serotypes, incidence in uncolonized children increased with age, suggesting that increasing exposure of older children to colonization may overcome any effect of serotype-specific immunity on age-specific incidence. Similarly, susceptibility to competition showed no consistent age pattern (Fig. 3C) . Figure 4 shows the ratio of the prevalence of a serotype among baseline samples to its appearance (as a new serotype) among follow-up samples, plotted against its baseline frequency. This distribution is approximately symmetric around 1 for the rare to intermediate serotypes, but the 14 most common serotypes at baseline tended to be more common among baseline samples. This is unsurprising in that the types most common at baseline are those with high incidence, long duration, and low susceptibility to competition (Table 2) , whereas presence at follow-up reflects only high incidence 4. Number of hosts in whom each serotype was isolated at baseline, compared with the ratio of hosts in whom it was isolated at baseline versus follow-up (note log scale on y-axis). For rarer serotypes, there was no tendency to be more common at baseline or at follow-up, whereas more common serotypes tended to be isolated more often at baseline than at follow-up.
Baseline Versus Follow-up Samples
and hence does not as strongly favor the high-prevalence types.
Co-occurrence of Serotypes
Of the 529 pairs of serotypes considered, 39 (7.4%) occurred more often than the 95% cutoff estimated from permutations, suggesting they might be unusually common (eTable 2). Of these, 14 (including 10 of the top 15) were pairs of the same serogroup, which might be expected to occur due to serotyping errors: an international validation study found that approximately 5% of serotypes are erroneous, mainly due to assignment of the wrong type within a serogroup. 46 These co-occurrences may also reflect the fact that small genetic changes can lead to expression of another serotype within a serogroup (eg, 15B-C, which account for the strongest 2 outliers in this analysis, differ by a point mutation and often "switch" in carriage studies 47, 48 ). The remaining 25 (4.7%) are consistent with the 5% that should occur by chance. These data show no evidence that certain pairs of serotypes tend to occur together in the same host.
DISCUSSION
The Kilifi longitudinal carriage study represents the largest and most intensively sampled data set to our knowledge for estimating basic parameters of pneumococcal acquisition, clearance, and competition. We have here applied a relatively high-dimensional Markov model to estimate these parameters, taking advantage of the scale of the dataset while maintaining some parametric assumptions that allow for simultaneous estimation of all of the parameters of interest.
A previous analysis of this data set 38 estimated, separately for each serotype, rates of acquisition and loss (clearance or replacement by another serotype), using a statistical model with only 2 states-(1) colonized with a focal serotype or (2) uncolonized/colonized with another serotype. That approach was much simpler and gave acquisition-and clearance-rate estimates strongly correlated with, but different from, those estimated here.
The more complex approach used here overcomes 3 limitations of the previous estimates. First, we separately estimate rates of immune clearance and rates of replacement by other serotypes. Second, the previous method violated the Markov assumption by combining very heterogeneous serotypes into the other category in the model for each serotype, which is less of a problem here with more states. Third, use of a single model here allows estimation of covariances in the different parameter estimates, aiding statistical analysis.
Even this model relies on simplifying assumptions that are violated in reality. For example, age strongly affects time to clearance, whereas a simple Markov model assumes that hosts are homogeneous. Although the age-specific analysis accounts for the major effects of age, it still leaves out further sources of interindividual heterogeneity in rates, such as exposure to others who are colonized, antimicrobial use, immune status unrelated to age, and others. We assume a constant hazard of each transition (acquisition, replacement with a new type, or clearance of the current type), which may be violated in reality. Antimicrobial use is not documented in this study. Because serotypes vary in their degree of antimicrobial resistance, 49 clearance by antimicrobial use will reduce the duration more in those serotypes that are more susceptible. Our estimates reflect the local patterns of antimicrobial use and serotype-specific resistance; the latter are relatively similar to those in other settings prior to conjugate vaccine introduction. 49 -51 Importantly, we do not explicitly account for simultaneous carriage of multiple serotypes, which cannot be detected by serotyping a single bacterial colony, as was the standard practice in this study. This omission may bias estimates of the competition parameter, although the direction of bias is unclear: observed changes in serotype may be due to changing detection of the already resident serotype (thus inflating rates of acquisition of new serotypes), but acquisition events may also be missed (thus reducing rates of acquisition of new types). Duration estimates will mainly be biased downward by failure to detect a serotype when another is present, although the requirement of 2 swabs negative for the baseline type should mitigate this bias. Prevalence estimates will be biased downward by failure to detect multiple colonization.
Despite these limitations, the results show a clear pattern. Highly prevalent serotypes have the longest time to clearance, the lowest susceptibility to being replaced by other types, and the highest incidence. From the perspective of bacterial population biology, these components of "fitness" tend to be positively correlated, suggesting that serotype has a major impact on many aspects of the bacteria's ability to spread and persist, and that those with higher fitness along one dimension tend to be fitter on other dimensions as well. Interestingly, a laboratory measure previously reported to correlate positively with prevalence-greater resistance to nonopsonic surface killing by human neutrophils 15 -also correlates with these other fitness measures. Although prevalence should correlate with these other components (because it is determined by them), further work is needed to understand other causal links among these laboratory and epidemiologic measures. Although some serotypes reduced detectable acquisition of other strains, there was little statistical evidence that carriage of any serotype facilitates acquisition of others. Biologically, it is expected that presence of a resident strain might inhibit acquisition of another strain, 27, 30, 36, 37 but there is no known mechanism by which the presence of a resident strain could promote acquisition of another strain.
We also find that, for many serotypes (especially the longest-lived), time to clearance decreases with age. This is consistent with earlier findings. 24, 30 In our study, by the time Epidemiology • Volume 23, Number 4, July 2012 Markov Transition Model children reach 41 months of age, the mean time to clearance is on the order of 1-3 months for most serotypes (less than half that for children Ͻ22 months), and time to clearance in these older children is no longer so closely correlated with other components of fitness. Reduced duration of carriage with age for many serotypes is consistent with the expectation from animal studies of the CD4 ϩ T-cell dependent responses acquired after exposure to pneumococcal carriage, which reduce the duration of pneumococci via immune responses not targeted at the capsular serotype. 23, 25 Reduced duration of carriage with age is also consistent with a maturation of the immune response with age, independent of exposure, which in another animal study was shown to hasten pneumococcal clearance. 40 Several longitudinal studies have estimated acquisition and loss parameters for pneumococcal serotypes. Precise comparison across studies is difficult because other studies have estimated acquisition rates conditional on the presence of a colonized person in the family 29, 31, 32 or school, 28 or because serotypes were grouped into heterogeneous groups. 28 Bangladeshi infants 32 cleared common serotypes somewhat faster (approximately 30 -40 days) than estimated in our study. Serotype-specific carriage durations (1-2 months) in Danish children (median age 1.9 years at enrollment) in day care were more similar to those observed here for children older than 41 months of age, perhaps because the higher prevalence in Danish day-care attendees had stimulated more rapid development of immunity. 27 Also, colonization was more protective (approximately 90%) against acquisition of a new serotype in that study than here. 27 These studies differed in sampling times, consideration of multiple carriage, and setting.
Precise estimates of serotype-specific epidemiologic parameters are important to understand coexistence of different serotypes 33, 52 and to understand the impact of vaccination on serotype dynamics. 13, 37, 53 Future studies should estimate similar parameters for the serotypes that are rare in unvaccinated populations but become common after vaccination.
